200 related articles for article (PubMed ID: 34553648)
1. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.
Li XB; Cao NW; Chu XJ; Zhou HY; Wang H; Yu SJ; Ye DQ; Li BZ
Ann Med; 2021 Dec; 53(1):1687-1695. PubMed ID: 34553648
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies.
Cai T; Zhao J; Yang Y; Jiang Y; Zhang JA
Lupus; 2022 Dec; 31(14):1714-1725. PubMed ID: 36325952
[TBL] [Abstract][Full Text] [Related]
4. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
5. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and risk factors of infection in patients with systemic lupus erythematosus: A systematic review and meta-analysis of observational studies.
Yuan Q; Xing X; Lu Z; Li X
Semin Arthritis Rheum; 2020 Oct; 50(5):1022-1039. PubMed ID: 32911280
[TBL] [Abstract][Full Text] [Related]
7. Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: A systematic review and meta-analysis.
Tao CY; Shang J; Chen T; Yu D; Jiang YM; Liu D; Cheng GY; Xiao J; Zhao ZZ
Medicine (Baltimore); 2019 Apr; 98(14):e15030. PubMed ID: 30946340
[TBL] [Abstract][Full Text] [Related]
8. Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: A systematic review and meta-analysis.
Babary H; Liu X; Ayatollahi Y; Chen XP; Doo L; Uppaluru LK; Kwak MK; Kulaga C; Modjinou D; Olech E; Yoo JW
Int J Rheum Dis; 2018 Jan; 21(1):84-92. PubMed ID: 28884965
[TBL] [Abstract][Full Text] [Related]
9. Patients with asthma have a higher risk of systemic lupus erythematosus: a systematic review and meta-analysis.
Charoenngam N; Ponvilawan B; Wongtrakul W; Ungprasert P
Clin Rheumatol; 2021 Feb; 40(2):529-536. PubMed ID: 32638252
[TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus increases risk of incident atrial fibrillation: A systematic review and meta-analysis.
Chen Y; Fu L; Pu S; Xue Y
Int J Rheum Dis; 2022 Oct; 25(10):1097-1106. PubMed ID: 35906745
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus: A meta-analysis.
Liu Y; Cheng Z; Zha B; Chen X; Gong Z; Ji L; Wei L
Lupus; 2023 Oct; 32(11):1310-1319. PubMed ID: 37699157
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: A meta-analysis.
Duan J; Ma D; Wen X; Guo Q; Gao J; Zhang G; Xu K; Zhang L
Lupus; 2021 Jun; 30(7):1163-1174. PubMed ID: 33853420
[TBL] [Abstract][Full Text] [Related]
14. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
[TBL] [Abstract][Full Text] [Related]
15. Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort.
Molad Y; Gorshtein A; Wysenbeek AJ; Guedj D; Majadla R; Weinberger A; Amit-Vazina M
Lupus; 2002; 11(6):356-61. PubMed ID: 12139373
[TBL] [Abstract][Full Text] [Related]
16. Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
Polanski JF; Tanaka EA; Barros H; Chuchene AG; Miguel PTG; Skare TL
Laryngoscope; 2021 Mar; 131(3):E957-E960. PubMed ID: 32603516
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and risk factors of patients with systemic lupus erythematosus and cancer].
Guo JY; Ren ZG; Xuan YY; Li TF; Liu XJ; Niu CZ; Li JY; Liu SY
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):218-221. PubMed ID: 32146749
[TBL] [Abstract][Full Text] [Related]
18. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.
Tsakonas E; Joseph L; Esdaile JM; Choquette D; Senécal JL; Cividino A; Danoff D; Osterland CK; Yeadon C; Smith CD
Lupus; 1998; 7(2):80-5. PubMed ID: 9541091
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study.
Prata AR; Luís M; Assunção H; da Silva JAP; Inês LS
Clin Rheumatol; 2022 Apr; 41(4):1069-1078. PubMed ID: 34782940
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis.
Bello N; Meyers KJ; Workman J; Hartley L; McMahon M
Lupus; 2023 Mar; 32(3):325-341. PubMed ID: 36547368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
